The Australian rifampicin trial.
D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002986:Clinical Trials as Topic; D004802:Eosinophilia / Q000139:chemically induced; D006801:Humans; D066298:In Vitro Techniques; D007408:Intestinal Absorption; D007538:Isoniazid / Q000008:administration & dosage; D007565:Jaundice / Q000139:chemically induced; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D009161:Mycobacterium / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity / Q000652:urine; D013921:Thrombocytopenia / Q000139:chemically induced; D000637:Transaminases / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D007770:L-Lactate Dehydrogenase; D000637:Transaminases; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin